priors.science/reviews/glp-1-receptor-agonists

GLP-1 Receptor Agonists

The current evidence on 39 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

39claims tracked
633primary papers reviewed
3 Jun 2026latest evidence review
Weeklyre-scored against new papers
3 Established · 14 Likely · 18 Uncertain · 4 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableSemaglutide 2.4 mg achieves 15% body weight lossMetabolicEstablished90%20
StableTirzepatide 15 mg achieves 20% body weight lossMetabolicEstablished90%19
StableReduce major adverse cardiovascular events in type 2 diabetes with established cardiovascular diseaseCardiovascularEstablished85%20
StableTirzepatide outperforms single GLP-1 receptor agonistsMetabolicLikely84%20
StableReduce obstructive sleep apnoeaNovelLikely84%20
StableWeight regain after discontinuationMetabolicLikely83%20
StableReduce all-cause mortality in type 2 diabetesCardiovascularLikely81%20
StableRenal protection and slower chronic kidney disease progressionMetabolicLikely81%20
StableSustained heart rate increase of 2-4 beats per minuteSafetyLikely81%20
StableNo overall gastrointestinal cancer increaseCancerLikely80%20
StableImprove non-alcoholic fatty liver diseaseMetabolicLikely80%20
StableCardiovascular benefit in non-diabetic obesityCardiovascularLikely79%20
StableIncrease gallbladder disease riskSafetyLikely79%20
StableNo increase in suicidalitySafetyLikely78%20
StableNo thyroid cancer increaseCancerLikely72%20
StableReduce heart failure hospitalisationCardiovascularLikely67%20
StableClinically significant lean mass lossSafetyLikely66%20
StableImprove polycystic ovary syndrome fertilityNovelUncertain64%20
StableImprove male reproductive functionNovelUncertain63%20
StableReduce Alzheimer's disease riskNeurodegenerationUncertain62%20
StableImprove psoriasis severityNovelUncertain61%20
StableReduce alcohol consumptionAddictionUncertain56%20
StableReduce peripheral arterial disease and limb eventsCardiovascularUncertain55%20
StableWorsen diabetic retinopathySafetyUncertain55%20
StableReduce neuroinflammation (microglial suppression)NeurodegenerationUncertain54%20
StableTirzepatide has better ocular safetySafetyUncertain52%17
StableModulate reward circuitryAddictionUncertain51%20
StableReduced colorectal cancer riskCancerUncertain51%14
StableReduce nicotine cravingsAddictionUncertain50%20
StableIncrease non-arteritic anterior ischaemic optic neuropathy riskSafetyUncertain50%20
StableSlow Parkinson's disease progressionNeurodegenerationUncertain45%20
StablePreserve brain glucose metabolismNeurodegenerationUncertain44%20
StableReduce opioid and stimulant useAddictionUncertain43%20
StableReduce atrial fibrillation recurrenceCardiovascularUncertain40%20
StableBone density and fracture riskSafetyUncertain40%20
StableReduce pancreatic cancer in pancreatitisCancerDoubtful35%20
StableImprove cognition in established Alzheimer's diseaseNeurodegenerationDoubtful35%20
StableReduce fibromyalgia symptomsNovelDoubtful35%20
StableImprove breast cancer disease-free survivalCancerDoubtful32%20
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic